Get informed when a big investor buys or sells
+ FollowOvervalued by 20.6% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $1.04 Billion |
|---|---|
| Enterprise Value | $948.14 Million |
| Earnings per Share | $3.29 |
| Beta | 0.41 |
| Outstanding Shares | 12,370,195 |
| P/E Ratio | 17.07 |
|---|---|
| PEG | 6.73 |
| Price to Sales | 2.47 |
| Price to Book Ratio | 6.46 |
| Enterprise Value to Revenue | 2.2 |
| Enterprise Value to EBIT | 7.68 |
| Enterprise Value to Net Income | 8 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.52 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Basilea Pharmaceutica AG is a revenue-generating biopharmaceutical company dedicated to developing innovative products to meet critical medical needs in both cancer treatment (oncology) and the fight against infections (anti-infectives)....